Question · asked by 1 review
Stopping LABA vs continuing use of LABA+ICS: Asthma‐related quality of life (MCID)
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Stopping LABA vs continuing use of LABA+ICS Asthma‐related quality of life 12 weeks · adults with asthma well controlled on LABA and ICS Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled… (2015) · Cochrane Headline outcomes only | no estimate extracted | 2 studies · 359 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.